This company has been marked as potentially delisted and may not be actively trading. IMARA (IMRA) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsInsider TradesTrendsBuy This Stock IMRA vs. MOR, GMTX, CALT, ZYME, MENS, SBTX, MBX, AVTE, NLTX, and CYBNShould you be buying IMARA stock or one of its competitors? The main competitors of IMARA include MorphoSys (MOR), Gemini Therapeutics (GMTX), Calliditas Therapeutics AB (publ) (CALT), Zymeworks (ZYME), Jyong Biotech (MENS), Silverback Therapeutics (SBTX), MBX Biosciences (MBX), Aerovate Therapeutics (AVTE), Neoleukin Therapeutics (NLTX), and Cybin (CYBN). IMARA vs. Its Competitors MorphoSys Gemini Therapeutics Calliditas Therapeutics AB (publ) Zymeworks Jyong Biotech Silverback Therapeutics MBX Biosciences Aerovate Therapeutics Neoleukin Therapeutics Cybin IMARA (NASDAQ:IMRA) and MorphoSys (NASDAQ:MOR) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, valuation, media sentiment, risk, earnings and profitability. Which has more volatility & risk, IMRA or MOR? IMARA has a beta of 1.09, suggesting that its stock price is 9% more volatile than the S&P 500. Comparatively, MorphoSys has a beta of 1.2, suggesting that its stock price is 20% more volatile than the S&P 500. Is IMRA or MOR more profitable? IMARA has a net margin of 0.00% compared to MorphoSys' net margin of -226.79%. IMARA's return on equity of 2.12% beat MorphoSys' return on equity.Company Net Margins Return on Equity Return on Assets IMARAN/A 2.12% 2.00% MorphoSys -226.79%-694.31%-22.55% Does the media prefer IMRA or MOR? In the previous week, IMARA had 1 more articles in the media than MorphoSys. MarketBeat recorded 1 mentions for IMARA and 0 mentions for MorphoSys. MorphoSys' average media sentiment score of 0.00 beat IMARA's score of 0.00 indicating that MorphoSys is being referred to more favorably in the news media. Company Overall Sentiment IMARA Neutral MorphoSys Neutral Do insiders & institutionals have more ownership in IMRA or MOR? 49.3% of IMARA shares are owned by institutional investors. Comparatively, 18.4% of MorphoSys shares are owned by institutional investors. 37.3% of IMARA shares are owned by insiders. Comparatively, 0.1% of MorphoSys shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Which has higher valuation & earnings, IMRA or MOR? IMARA has higher earnings, but lower revenue than MorphoSys. MorphoSys is trading at a lower price-to-earnings ratio than IMARA, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIMARAN/AN/A$1.49M$0.05768.80MorphoSys$238.28M11.99-$205.35M-$3.48-5.45 SummaryIMARA beats MorphoSys on 9 of the 12 factors compared between the two stocks. Get IMARA News Delivered to You Automatically Sign up to receive the latest news and ratings for IMRA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IMRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMRA vs. The Competition Export to ExcelMetricIMARAPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.01B$784.84M$5.52B$9.37BDividend YieldN/A4.84%4.74%4.12%P/E Ratio768.951.3728.8823.80Price / SalesN/A25.69440.8796.33Price / Cash75.2419.5635.0756.59Price / Book11.176.688.255.54Net Income$1.49M-$3.67M$3.25B$259.97M IMARA Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMRAIMARAN/A$38.44-3.7%N/AN/A$1.01BN/A768.9541Gap DownMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730GMTXGemini TherapeuticsN/A$59.38+2.8%N/A+36.3%$2.57BN/A-59.3830High Trading VolumeCALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180ZYMEZymeworks2.8692 of 5 stars$14.32flat$21.00+46.6%+23.2%$997.86M$93.38M-9.55460Upcoming EarningsMENSJyong BiotechN/A$10.06-8.5%N/AN/A$836.30MN/A0.0031Positive NewsQuiet Period ExpirationSBTXSilverback TherapeuticsN/A$17.85-0.4%N/A+73.5%$643.64MN/A-7.3883High Trading VolumeMBXMBX Biosciences2.6471 of 5 stars$11.70-4.0%$37.57+221.1%N/A$391.06MN/A0.0036News CoverageAVTEAerovate TherapeuticsN/A$8.69-8.2%N/A-88.6%$251.88MN/A-2.9120High Trading VolumeNLTXNeoleukin TherapeuticsN/A$22.34-1.2%N/A-46.2%$209.95MN/A-7.1890Gap DownHigh Trading VolumeCYBNCybin2.5771 of 5 stars$7.73-3.7%$85.00+999.6%N/A$177.98MN/A-1.7650 Related Companies and Tools Related Companies MorphoSys Alternatives Gemini Therapeutics Alternatives Calliditas Therapeutics AB (publ) Alternatives Zymeworks Alternatives Jyong Biotech Alternatives Silverback Therapeutics Alternatives MBX Biosciences Alternatives Aerovate Therapeutics Alternatives Neoleukin Therapeutics Alternatives Cybin Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMRA) was last updated on 8/3/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredEx-Hedge Fund Manager Uncovers $100 Trillion Land ShiftTrump's Radical New Plan Could Enrich Thousands This isn't a campaign stunt. It's a $100 trillion move to u...Stansberry Research | SponsoredInvestigating the Most Controversial Stock on EarthTesla’s wild price swings may not be random after all. Hedge fund veteran Larry Benedict has uncovered a st...Brownstone Research | SponsoredThis New Rule Could Change EverythingA major change is quietly going into effect this July — and Wall Street is already positioning for it. Big ...American Alternative | SponsoredSell these "safe" blue chips immediatelyInvesting Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another...InvestorPlace | SponsoredToo busy to trade? Good.Too busy to trade? That might be your edge. This after-hours strategy is built for people who don’t sit at ...Timothy Sykes | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IMARA Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IMARA With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
